Larimar Therapeutics Inc. is a publicly held clinical-stage biotechnology company focused on developing treatments for patients with rare diseases. The company's expertise lies in its novel cell-penetrating peptide technology platform and aims to lead in the treatment of rare diseases. With a strong management team, Larimar is committed to leveraging its technology and know-how for successful product development.